JP2017502989A - 組合せ医薬 - Google Patents

組合せ医薬 Download PDF

Info

Publication number
JP2017502989A
JP2017502989A JP2016546785A JP2016546785A JP2017502989A JP 2017502989 A JP2017502989 A JP 2017502989A JP 2016546785 A JP2016546785 A JP 2016546785A JP 2016546785 A JP2016546785 A JP 2016546785A JP 2017502989 A JP2017502989 A JP 2017502989A
Authority
JP
Japan
Prior art keywords
cancer
combination
pharmaceutically acceptable
acceptable salt
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016546785A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017502989A5 (enExample
Inventor
ヒラワット，サミット
マサケシ，クリスティアン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2017502989A publication Critical patent/JP2017502989A/ja
Publication of JP2017502989A5 publication Critical patent/JP2017502989A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016546785A 2014-01-15 2015-01-13 組合せ医薬 Withdrawn JP2017502989A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14305057 2014-01-15
EP14305057.3 2014-01-15
PCT/IB2015/050260 WO2015107461A1 (en) 2014-01-15 2015-01-13 Pharmaceutical combinations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019167076A Division JP2020023497A (ja) 2014-01-15 2019-09-13 組合せ医薬

Publications (2)

Publication Number Publication Date
JP2017502989A true JP2017502989A (ja) 2017-01-26
JP2017502989A5 JP2017502989A5 (enExample) 2018-02-22

Family

ID=50033443

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016546785A Withdrawn JP2017502989A (ja) 2014-01-15 2015-01-13 組合せ医薬
JP2019167076A Pending JP2020023497A (ja) 2014-01-15 2019-09-13 組合せ医薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019167076A Pending JP2020023497A (ja) 2014-01-15 2019-09-13 組合せ医薬

Country Status (11)

Country Link
US (2) US20160331755A1 (enExample)
EP (1) EP3094340A1 (enExample)
JP (2) JP2017502989A (enExample)
KR (1) KR20160101027A (enExample)
CN (2) CN112535688A (enExample)
AU (2) AU2015207723A1 (enExample)
BR (1) BR112016012141A2 (enExample)
CA (1) CA2936783A1 (enExample)
MX (1) MX2016009226A (enExample)
RU (2) RU2020121929A (enExample)
WO (1) WO2015107461A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111757734A (zh) * 2017-12-28 2020-10-09 星座制药公司 通过组合疗法的ezh2抑制剂的药代动力学增强
CN115040523A (zh) * 2021-03-09 2022-09-13 上海翰森生物医药科技有限公司 Pi3k抑制剂联合雌激素受体拮抗剂在治疗肿瘤疾病中的用途
WO2023150267A1 (en) * 2022-02-03 2023-08-10 Maison Amori Oqvpo Llc Methods, compositions and uses for treating cancer by providing medications that induce targeted tumor cell mitosis before providing chemotherapy or radiation and kits therefor

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物
JP2008528469A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
JP2009527464A (ja) * 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
JP2010526120A (ja) * 2007-05-09 2010-07-29 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
EP2558463A1 (en) * 2010-04-14 2013-02-20 Incyte Corporation Fused derivatives as i3 inhibitors
WO2012009649A1 (en) * 2010-07-16 2012-01-19 Anderson Gaweco Mif inhibitors and their uses
CN103764144B (zh) * 2011-08-31 2016-07-20 诺华股份有限公司 Pi3k抑制剂与mek抑制剂的协同组合
CA2867700A1 (en) * 2012-03-23 2013-09-26 Memorial Sloan-Kettering Cancer Center Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
WO2015081127A2 (en) * 2013-11-26 2015-06-04 Gilead Sciences, Inc. Therapies for treating myeloproliferative disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008528469A (ja) * 2005-01-21 2008-07-31 アステックス・セラピューティクス・リミテッド ピラゾールキナーゼ阻害剤およびさらなる抗癌剤の組合せ剤
JP2009527464A (ja) * 2006-01-20 2009-07-30 ノバルティス アクチエンゲゼルシャフト Ｐｉ−３キナーゼ阻害剤として使用されるピリミジン誘導体
CN101019828A (zh) * 2007-03-23 2007-08-22 济南帅华医药科技有限公司 一种含磷酸肌醇3－激酶抑制剂及激素类药物的抗癌组合物
JP2010526120A (ja) * 2007-05-09 2010-07-29 ノバルティス アーゲー Ｐｉ３ｋ脂質キナーゼ阻害剤としての置換イミダゾピリダジン
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物

Also Published As

Publication number Publication date
CN105916515A (zh) 2016-08-31
JP2020023497A (ja) 2020-02-13
EP3094340A1 (en) 2016-11-23
RU2016133285A (ru) 2018-02-20
CA2936783A1 (en) 2015-07-23
MX2016009226A (es) 2016-10-05
WO2015107461A1 (en) 2015-07-23
AU2017245302A1 (en) 2017-11-02
US20160331755A1 (en) 2016-11-17
KR20160101027A (ko) 2016-08-24
RU2016133285A3 (enExample) 2018-08-28
CN112535688A (zh) 2021-03-23
US20170304311A1 (en) 2017-10-26
AU2017245302B2 (en) 2019-04-04
RU2020121929A (ru) 2020-07-13
AU2015207723A1 (en) 2016-06-09
BR112016012141A2 (pt) 2017-08-08
US10085996B2 (en) 2018-10-02

Similar Documents

Publication Publication Date Title
JP6595024B2 (ja) Ｂ−Ｒａｆ阻害薬、ＥＧＦＲ阻害薬及び場合によってはＰＩ３Ｋ−α阻害薬を含む組合せ医薬
US20250127796A1 (en) Methods of treating cancer with pi3k inhibitor, gdc-0077
US20210322426A1 (en) Methods of treating cancer with pi3k alpha inhibitors and metformin
US20160129003A1 (en) Pharmaceutical Combinations
JP2026016396A (ja) 乳がんの治療のための併用療法
US20200230109A1 (en) Compounds for treating tnbc
JP2020023497A (ja) 組合せ医薬
JP2016520662A (ja) Ｐｉ３ｋ阻害剤および微小管不安定化剤の医薬組み合わせ
US20180353495A1 (en) Pharmaceutical combinations comprising a pi3k inhibitor for the treatment of cancer
KR102356393B1 (ko) 두경부암의 치료 또는 예방에 사용하기 위한 pi3 키나제 억제제와 파클리탁셀의 조합물
HK40104421A (en) Methods of treating cancer with pi3k inhibitor, gdc-0077

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180110

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180110

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190304

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190514

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190913

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20191001

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20191021